Formalized nurse-led care support after an acute leukemia diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized interventional study comparing a short period of structured, nurse-delivered care support given soon after the announcement of an acute leukemia diagnosis to usual care. Eligible adult patients (26–79 years) with a new, untreated acute leukemia hospitalized at Centre Henri Becquerel who can consent are randomized to receive the accompaniment within 7 days or to a control group. Anxiety and quality of life (QLQ-C30) are measured at baseline (T0), again shortly after the intervention or equivalent time (T1), and at two months (±3 days) after ICU admission (T2), with satisfaction and program-evaluation questionnaires collected at T2. The primary outcome is change in anxiety between groups, and both groups receive usual medical care throughout.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* informed consent signed
* medical confirmation of acute leukemia diagnosis
* age equal of superior to 26 years and under 80 years
* confirmed diagnosis not yet treated
* hospitalization at Centre Henri Becquerel
* member or beneficiary of a social security

Exclusion Criteria:

* -Patient unable to understand the study for any reason or to comply with the trial's requirements
* Patient in relapse of acute leukemia
* Patient diagnosed with acute myeloid leukemia 3
* History of cancer within the 5 years preceding the year of study enrollment
* Alcohol and drug abuse
* Inclusion in another therapeutic trial that prevents further enrollment in a trial evaluating quality of life or psychological well-being
* Diagnosed psychiatric illness
* Patient under guardianship, curatorship, or legal protection

Where it's running

• Centre Henri Becquerel
  Rouen, France Recruiting

Study contacts

• Principal investigator: Fabrice Jardin, Md PhD — Centre Henri Becquerel
• Study coordinator: Johan Le Fel, PhD
• Email: johan.lefel@chb.unicancer.fr
• Phone: +232082918

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Menin inhibitors in pediatric relapsed or refractory acute leukemia

  This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898436

• Artistic and movement activities to help anxiety in kids with ALL

  Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.

  Recruiting Phase 3 Children's Cancer Hospital Egypt 57357 · Cairo, Cairo Governorate · NCT07878065

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers

  This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.

  Recruiting Phase 1 Laguna Biotherapeutics, Inc. · Palo Alto, California · NCT07573111

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

• Menin inhibitor maintenance after allogeneic stem cell transplant

  This project will try menin inhibitor maintenance to see if it helps people with acute leukemia after allogeneic stem cell transplant who have KMT2A or related gene changes.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07559695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.